Asarfi Hospital Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Asarfi Hospital Ltd. on BSE

Load latest

Asarfi Hospital Ltd.

04 Jun 2025

123.95

2.44%

Company Update

Asarfi Hospital Ltd - 543943 - Appointment of Company Secretary and Compliance Officer

BSE India

We wish to inform you that the Board of Director of the Company, at its meeting held on 03/06/2025 has approved the appointment of CS.Sudipa Singh as the Company Secretary and Compliance Officer of the Comapny With effect from 03/06/2025 in terms of Regulation 6 of the SEBI listing regulation.

pdf

Asarfi Hospital Ltd.

04 Jun 2025

123.95

2.44%

Corp. Note

Asarfi Hospital Ltd - 543943 - Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI …

BSE India

we wish to inform you that the Board of Directors of the Company, at its meeting held on 03/06/2025 has approved the appointment of CS.SUDIPA SINGH as the Company Secretary and Compliance Officer of the Company with effect from 03/06/2025 in terms of Regulation 6 of the SEBI listing regulations.

pdf

Asarfi Hospital Ltd.

24 May 2025

123.95

2.44%

Corp. Note

Asarfi Hospital Ltd - 543943 - Integrated Filing (Financial)

BSE India

We wish you to inform you that the board of director of asarfi hospital limited at its meeting held on 08Th May,2025 has considered and approved the audited statndalone and consolidated Financial Results of the company for the standalone & consilidated quarter ended & year ended 31st March,2025.

pdf

Asarfi Hospital Ltd.

19 May 2025

123.95

2.44%

Company Update

Asarfi Hospital Ltd - 543943 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

We wish to Inform that Asarfi Hospital Limited has signed a Memorandum of Undersatanding ( MoU) with Gleneagles Hospital, Chennai, to set up Jharkhand''s first Multi Organ Transplant Unit at our hospital in Dhanbad.

pdf

Asarfi Hospital Ltd.

14 May 2025

123.95

2.44%

Earnings Call

Asarfi Hospital Ltd - 543943 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

We are enclosing herewith trasncript of earning conference call held on May12, 2025, wherein Audited standalone & Consolidated Financial result for the 2nd half year ended March 31, 2025 (FY2025) were discussed. The said transcript is also available in the investor senction of our website.

pdf

Asarfi Hospital Ltd.

12 May 2025

123.95

2.44%

Company Update

Asarfi Hospital Ltd - 543943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

we hereby inform that the company had participated in Investor Meet (One to one meet) organized by Chorus Call Conferencing Services (I) Pvt. Ltd. on May 12, 2025 through virtual meeting. Mr. Udai Pratap Singh (Managing Director), Mr. Harendra Singh (CFO), Navin Kumar (VP Finance) & Suraj Hazari (Chief Manager Finance) have participated in the said meet from the Company's side.

pdf

Asarfi Hospital Ltd.

09 May 2025

123.95

2.44%

Company Update

Asarfi Hospital Ltd - 543943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

We wish to inform you that we have scheduled a conference call with analyst/investors on Monday, May 12, 2025, at 16:00 PM InST, inter alia, to discuss the Audited financial results for the Quarter ended and year ended March 31, 2025.

pdf

Asarfi Hospital Ltd.

09 May 2025

123.95

2.44%

Investor Presentation

Asarfi Hospital Ltd - 543943 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

We here present the Investor Presentation of the company for the quarter and year ended March 31, 2025.

pdf

Asarfi Hospital Ltd.

09 May 2025

123.95

2.44%

Annual Report

Annual report for Asarfi Hospital Ltd. for FY-2025

None

pdf

Asarfi Hospital Ltd.

08 May 2025

123.95

2.44%

Result

Asarfi Hospital Ltd - 543943 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

We wish to inform you that the Board of Directors of Asarfi Hospital Limited (the Company), at its meeting held today i.e. on 08TH May, 2025 has considered and approved the audited Standalone and Consolidated Financial Results of the Company for the Standalone & Consolidated quarter ended & year ended 31st March, 2025.

pdf